This price target is based on 0 analysts offering 12 month price targets for Premaitha Health in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a NaN upside from the last price of GBX 0.
The current consensus among 0 investment analysts is to n/a stock in Premaitha Health. This N/A consensus rating has held steady for over two years.
Premaitha Health PLC, a molecular diagnostic company, develops tests for non-invasive prenatal screening and other applications in the United Kingdom and internationally. The company develops the IONA Test, an in vitro diagnostic non-invasive pre-natal screening test for pregnant women to estimate Down's syndrome, Edward's syndrome, and Patau's syndrome. The IONA test is a diagnostic system that enables clinical laboratory customers to perform the test in their own facilities. The company is headquartered in Manchester, the United Kingdom.